BioVersys initiates Phase 2b trial for anti infective drug BV100
Biotechnology company BioVersys enrolled the first patient in its Phase 2b trial evaluating anti infective drug candidate BV100 for treating drug resistant bacterial pneumonia
BioVersys AG, a clinical-stage biopharmaceutical company based in Switzerland, has initiated a Phase 2b trial for its anti-infective drug BV100. The trial, named RIV-CARE, aims to test the effectiveness of BV100 in combination with low-dose polymyxin B against hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex.
The study is expected to enroll around 100 patients across multiple geographies and compare the efficacy of BV100 plus low-dose polymyxin B with best available therapy. The trial, conducted by the ADVANCE-ID clinical trial network, is supported by funding from Wellcome, a UK-based global health organization. BioVersys CEO Dr. Marc Gitzinger expressed optimism about the trial's potential to provide real-world evidence for clinical practice in settings with high drug resistance levels.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
